JP2001503737A5 - - Google Patents

Download PDF

Info

Publication number
JP2001503737A5
JP2001503737A5 JP1998514271A JP51427198A JP2001503737A5 JP 2001503737 A5 JP2001503737 A5 JP 2001503737A5 JP 1998514271 A JP1998514271 A JP 1998514271A JP 51427198 A JP51427198 A JP 51427198A JP 2001503737 A5 JP2001503737 A5 JP 2001503737A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998514271A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001503737A (ja
Filing date
Publication date
Priority claimed from GBGB9619757.9A external-priority patent/GB9619757D0/en
Application filed filed Critical
Publication of JP2001503737A publication Critical patent/JP2001503737A/ja
Publication of JP2001503737A5 publication Critical patent/JP2001503737A5/ja
Ceased legal-status Critical Current

Links

JP51427198A 1996-09-21 1997-09-15 糖尿病の発生を防止するためのシブトラミン類似体の利用 Ceased JP2001503737A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9619757.9A GB9619757D0 (en) 1996-09-21 1996-09-21 Chemical process
GB9619757.9 1996-09-21
PCT/EP1997/005039 WO1998011884A1 (en) 1996-09-21 1997-09-15 Use of sibutramine analogues to prevent the development of diabetes

Publications (2)

Publication Number Publication Date
JP2001503737A JP2001503737A (ja) 2001-03-21
JP2001503737A5 true JP2001503737A5 (enExample) 2005-04-07

Family

ID=10800326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51427198A Ceased JP2001503737A (ja) 1996-09-21 1997-09-15 糖尿病の発生を防止するためのシブトラミン類似体の利用

Country Status (26)

Country Link
US (3) US6174925B1 (enExample)
EP (1) EP0927028A1 (enExample)
JP (1) JP2001503737A (enExample)
KR (1) KR20000048501A (enExample)
CN (1) CN1237905A (enExample)
AU (1) AU724488B2 (enExample)
BG (1) BG64473B1 (enExample)
BR (1) BR9711517A (enExample)
CA (1) CA2266401C (enExample)
CZ (1) CZ93699A3 (enExample)
GB (1) GB9619757D0 (enExample)
HR (1) HRP970505A2 (enExample)
HU (1) HUP9904026A3 (enExample)
ID (1) ID18320A (enExample)
IL (1) IL128850A (enExample)
MY (1) MY116150A (enExample)
NO (1) NO991358D0 (enExample)
NZ (1) NZ334580A (enExample)
PL (1) PL332305A1 (enExample)
RU (1) RU2245709C2 (enExample)
SK (1) SK31999A3 (enExample)
TR (1) TR199900618T2 (enExample)
TW (1) TW580385B (enExample)
UA (1) UA64726C2 (enExample)
WO (1) WO1998011884A1 (enExample)
ZA (1) ZA978450B (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process
JP2000080047A (ja) * 1998-06-30 2000-03-21 Takeda Chem Ind Ltd 医 薬
DK1093370T3 (da) * 1998-06-30 2006-05-22 Takeda Pharmaceutical Farmaceutisk præparat til behandling af diabetes
US6476078B2 (en) * 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6331571B1 (en) 1998-08-24 2001-12-18 Sepracor, Inc. Methods of treating and preventing attention deficit disorders
US6339106B1 (en) 1999-08-11 2002-01-15 Sepracor, Inc. Methods and compositions for the treatment and prevention of sexual dysfunction
US6974838B2 (en) 1998-08-24 2005-12-13 Sepracor Inc. Methods of treating or preventing pain using sibutramine metabolites
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
DZ2937A1 (fr) * 1998-11-12 2004-03-15 Smithkline Beecham Plc Compositions nouvelles de sensibilidants à l'insuline.
WO2000028989A1 (en) * 1998-11-12 2000-05-25 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US6696495B2 (en) 1998-12-02 2004-02-24 Snowden Pharmaceuticals, Llc Treatment of disorders secondary to organic impairments
US6323242B1 (en) 1998-12-02 2001-11-27 Peter Sterling Mueller Treatment of disorders secondary to organic impairments
US6552087B1 (en) 1999-03-19 2003-04-22 Abbott Gmbh & Co. Kg Therapeutic agent comprising (+)-sibutramine
US6723717B1 (en) 1999-06-01 2004-04-20 The University Of Texas Southwestern Medical Center Sulfur-containing thyroxane derivatives and their use as hair growth promotors
US6680344B1 (en) 1999-06-01 2004-01-20 The University Of Texas Southwestern Medical Center Method of treating hair loss using diphenylmethane derivatives
AR018699A1 (es) 1999-06-01 2001-11-28 Procter & Gamble Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afecta al corazon
GB9914744D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
US6399826B1 (en) 1999-08-11 2002-06-04 Sepracor Inc. Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain
US6610887B2 (en) 2001-04-13 2003-08-26 Sepracor Inc. Methods of preparing didesmethylsibutramine and other sibutramine derivatives
US8911781B2 (en) 2002-06-17 2014-12-16 Inventia Healthcare Private Limited Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
HRP20050307A2 (en) * 2002-10-05 2006-12-31 Hanmi Pharm. Co. Ltd. Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate
US20050131074A1 (en) * 2003-08-04 2005-06-16 Beckman Kristen M. Methods for treating metabolic syndrome
UY28457A1 (es) * 2003-08-07 2005-03-31 Sb Pharmco Inc Nueva composición
GB0318824D0 (en) * 2003-08-11 2003-09-10 Glaxo Group Ltd Novel composition
PL1677792T3 (pl) * 2003-10-31 2016-05-31 Takeda Pharmaceuticals Co Stały preparat zawierający pioglitazon, glimepiryd i ester polioksyetylenosorbitanu z kwasem tłuszczowym
KR100627687B1 (ko) * 2005-04-20 2006-09-25 주식회사 씨티씨바이오 시부트라민 유리염기 함유 조성물 및 이의 제조방법
CA2636324C (en) * 2006-01-06 2012-03-20 Sepracor Inc. Cycloalkylamines as monoamine reuptake inhibitors
WO2008034142A2 (en) 2006-09-15 2008-03-20 Reviva Pharmaceuticals, Inc. Synthesis, methods of using, and compositions of cycloalkylmethylamines
KR100812538B1 (ko) * 2006-10-23 2008-03-11 한올제약주식회사 약물 제어방출형 메트포르민-글리메피리드 복합제제
BRPI0716002A2 (pt) * 2006-11-22 2013-07-30 Sk Chemicals Co Ltd complexo de inclusço, processo de preparaÇço de um complexo de inclusço e composiÇço de tratamento e prevenÇço de hipocondria e obesidade
EP2118123B1 (en) 2007-01-31 2015-10-14 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP3159352B1 (en) 2007-03-28 2023-08-02 President and Fellows of Harvard College Stitched polypeptides
US20110024043A1 (en) 2009-07-02 2011-02-03 Dexcom, Inc. Continuous analyte sensors and methods of making same
WO2012003501A2 (en) 2010-07-02 2012-01-05 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9238625B2 (en) 2011-12-30 2016-01-19 Reviva Pharmaceuticals, Inc. Compositions, synthesis, and methods of using phenylcycloalkylmethylamine derivatives
NZ627528A (en) 2012-02-15 2016-05-27 Aileron Therapeutics Inc Peptidomimetic macrocycles
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52768B1 (en) * 1981-04-06 1988-02-17 Boots Co Ltd 1-arylcyclobutylalkylamine compounds useful as therapeutic agents
GB8531071D0 (en) * 1985-12-17 1986-01-29 Boots Co Plc Therapeutic compound
GB8704777D0 (en) * 1987-02-28 1987-04-01 Boots Co Plc Medical treatment
JP2675573B2 (ja) * 1988-03-31 1997-11-12 科研製薬株式会社 脳機能改善剤
IE61928B1 (en) * 1988-11-29 1994-11-30 Boots Co Plc Treatment of obesity
WO1995010292A1 (en) 1993-10-14 1995-04-20 Biomedica California, Inc. Diabetes treatment and prophylaxis
US5459164A (en) * 1994-02-03 1995-10-17 Boots Pharmaceuticals, Inc. Medical treatment
GB9619757D0 (en) * 1996-09-21 1996-11-06 Knoll Ag Chemical process

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000514337A5 (enExample)
JP2000500076A5 (enExample)
JP2000511019A5 (enExample)
JP2000513390A5 (enExample)
JP2000501324A5 (enExample)
JP2000510176A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000501338A5 (enExample)
JP2000501825A5 (enExample)
JP2001503038A5 (enExample)
JP2001507069A5 (enExample)
JP2000502485A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000513450A5 (enExample)
JP2001503737A5 (enExample)
JP2000502570A5 (enExample)
JP2000511105A5 (enExample)
JP2000501876A5 (enExample)